Intec Pharma Ltd (NASDAQ:NTEC)’s stock price traded up 6.6% during trading on Thursday . The stock traded as high as $3.39 and last traded at $3.39, 278,472 shares traded hands during trading. A decline of 3% from the average session volume of 286,250 shares. The stock had previously closed at $3.18.

Several equities research analysts recently commented on the stock. Maxim Group reiterated a “buy” rating and set a $12.00 price target on shares of Intec Pharma in a research note on Thursday, June 20th. Zacks Investment Research lowered shares of GENEL ENERGY PL/ADR from a “buy” rating to a “hold” rating in a research note on Tuesday, May 7th. LADENBURG THALM/SH SH reiterated a “buy” rating and set a $15.00 price target on shares of Intec Pharma in a research note on Thursday, June 20th. HC Wainwright set a $35.00 price target on shares of Stemline Therapeutics and gave the stock a “buy” rating in a research note on Thursday, June 20th. Finally, ValuEngine upgraded shares of WPP from a “sell” rating to a “hold” rating in a research note on Wednesday, June 19th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $12.17.

The stock has a 50 day simple moving average of $4.39. The company has a market cap of $111.28 million, a PE ratio of -2.42 and a beta of 0.28.

Intec Pharma (NASDAQ:NTEC) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.32) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.05. On average, analysts anticipate that Intec Pharma Ltd will post -1.05 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Private Advisors LLC acquired a new position in Intec Pharma in the first quarter valued at $225,000. Menta Capital LLC acquired a new position in Intec Pharma in the first quarter valued at $248,000. BlackRock Inc. acquired a new position in Intec Pharma in the fourth quarter valued at $67,000. Sigma Planning Corp acquired a new position in Intec Pharma in the first quarter valued at $183,000. Finally, Knott David M increased its stake in Intec Pharma by 2.5% in the first quarter. Knott David M now owns 290,434 shares of the biotechnology company’s stock valued at $2,129,000 after purchasing an additional 6,961 shares during the period. Institutional investors own 33.64% of the company’s stock.

About Intec Pharma (NASDAQ:NTEC)

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

See Also: Why Net Income is Important to Investors

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.